NSUN2 and prostate carcinoma: We evaluated the correlation between NSUN2 expression and chemotherapy sensitivity and observed that patients with lower NSUN2 expression responded more sensitively to most chemotherapeutic agents, such as docetaxel and cisplatin, etc. This suggests that NSUN2 may provide new options for choosing appropriate chemotherapy drugs for prostate cancer patients.